The suit alleges Bio-Rad fired its former general counsel for pursuing an investigation into bribery committed by the company's employees and agents in China.
Both groups are making their detailed protocols available to researchers online.
Low-pass sequencing and digital PCR analysis of cell-free circulating tumor DNA could detect metastatic disease in primary breast cancer patients months before clinical diagnosis.
On a currency-neutral basis, quarterly revenues increased about 1 percent compared to the same quarter last year.
Several early-access customers presented results from the 10X technology at the meeting.
Bio-Rad reported $598.2 million in revenues for the quarter, down from $602.6 million a year ago but surpassing the average analysts' estimate of $593.4 million.
The research may prove relevant to understanding human diversity as well as the genetic underpinning of certain CNV-related disorders.
An increasing number of publications using droplet-based digital PCR platforms suggests acceptance and uptake of the technology.
The company plans to launch a PCR-based test for measuring three genes in the plasma of lung cancer patients and is also at work on an NGS-based panel.
Officials from Exact Sciences, Cepheid, Bio-Rad, Biocartis, and NanoString provided strategic updates at the conference.
Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.
Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.
Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.
In Nature this week: sequenced genomes of five additional Neanderthals, and more.